Developer docs
API playgroundTry for free, no card

Search company profiles

StemCyte

Full company profile

uuid0002nbd

Namestring
StemCyte
Legal namestring
StemCyte, Inc.
Websiteurl
stemcyte.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

StemCyte, Inc. is a privately held U.S. cord blood banking and regenerative therapeutics company founded in 1997 and headquartered in Baldwin Park, California. The company operates a dual private-and-public cord blood bank under a single cGMP, FDA-licensed (US License 2280), FACT- and AABB-accredited platform. Its consumer-facing banking service offers annual, 18-year prepaid, and lifetime cord blood and cord tissue storage plans sold direct-to-consumer to U.S. expectant parents through a five-language website and an inside-sales call center, with add-on modules including MaxCell® premium processing, Newborn Genetic Analysis (a 258-gene NGS panel), Public Bank Access tiers, HLA typing, and a bundled LifeSaver Guarantee. Published lifetime MSRP is $5,625, positioned as the lowest among the five major U.S. private cord blood banks.

StemCyte generates revenue through a mix of one-time private-banking enrollment fees, recurring storage annuities, transaction-fee add-ons, B2B sales of cord-derived cellular materials (cord blood, Wharton's Jelly MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions and biotech developers, and long-tail licensing/royalty upside from REGENECYTE® (HPC, Cord Blood), an FDA-licensed allogeneic hematopoietic progenitor cell therapy with RMAT designation for Long COVID. The Biologics division is supported by a sponsored clinical pipeline across Long COVID, acute ischemic stroke, cerebral palsy, and a collaborative IMPAACT P1107 HIV cure study, plus an FDA-cleared Expanded Access Program for Long COVID.

Since 1997, StemCyte has delivered more than 2,300 cord blood units to over 325 transplant centers in 40 countries. Its customer base spans U.S. consumers (long-tail, one-decision-per-birth), B2B research buyers at institutions such as City of Hope, USC, CHLA, and UCLA, clinical trial sponsors, and — as of November 2025 — insurance-linked distribution partners beginning with Taishin Life in Taiwan. The company is privately held, with Diamond Biofund having invested US$6.35 million as part of a broader capital raise exceeding US$25 million announced in November 2023, alongside plans for a Taiwan Innovation Board listing.

Short descriptiontext

StemCyte is a privately held U.S. cord blood bank and regenerative therapeutics company founded in 1997, operating private and public cord blood banking alongside FDA-licensed REGENECYTE® cell therapy, serving expectant parents, academic researchers, and clinical trial sponsors across 40 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBaldwin Park, United States
HQ citystring
Baldwin Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cord blood banking, cellular therapy products, stem cell therapeutics, biological materials supply, regenerative medicine research
Industry4 codes
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Blood and Organ Banks621991
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Cord Blood Banking Services
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model7 records
1Private cord blood banking plans
TypeSubscription Recurring
Description

One-time enrollment revenue for cord blood and cord tissue storage plans (annual, 18-year prepaid, and lifetime options), plus optional split-pay over 6 or 12 months. The published lifetime cord blood plan is $5,625 MSRP — positioned as the lowest among the five major US private banks. Stored inventory scales with the number of enrolled families and forms a recurring annual storage annuity.

stemcyte.com
2Advanced Protection add-ons
TypeTransaction Fee
Description

One-time transaction-fee add-ons layered onto any private banking plan: MaxCell® premium processing, Newborn Genetic Analysis ($399), Public Bank Access ($299, covers the child) and Public Bank Access+ ($699, extends to parents). Each represents an incremental transaction with no recurring obligation.

stemcyte.com
3LifeSaver Guarantee and warranty economics
TypeManaged Services
Description

LifeSaver Guarantee is bundled free with every plan but creates contingent liability and a potential $50,000 payout obligation plus replacement unit from the public bank in the rare event of engraftment failure — a financial-services-style risk pool that is part of the value proposition and pricing logic.

stemcyte.com
4Biologics — cellular materials and research supply
TypeTransaction Fee
Description

B2B revenue from selling cord-derived cellular materials (whole cord blood units, cord tissue/Wharton's Jelly, MSCs, CD34+ HSPCs ≥90% purity, MSC exosomes, a cord blood cellular therapy product) as research-use and co-development starting materials to academic institutions, biotech developers, and clinical-trial sponsors. Includes custom specifications and pooled-donor formats on request.

stemcyte.com
5Clinical development and licensing (REGENECYTE®)
TypeLicensing Royalties
Description

Long-term value capture from REGENECYTE®, an FDA-licensed allogeneic HPC, Cord Blood therapy with RMAT designation for Long COVID, an FDA-cleared Expanded Access Program (2026), and three sponsored clinical trials (Long COVID Phase IIa, acute ischemic stroke Phase II, cerebral palsy Phase II). Includes data licensing, partnership, and future commercialization revenue tied to the cell therapy pipeline.

stemcyte.com
6Professional services — HLA typing and post-sale add-ons
TypeProfessional Services
Description

One-time services such as HLA typing on privately banked units (so the unit's profile can be searched against registries if a family member needs treatment), Newborn Genetic Analysis reporting, and post-18-year continuing storage at $200/year or prepaid lifetime lock-in.

stemcyte.com
7Insurance-linked distribution partnerships
TypeAffiliate Referral
Description

Revenue share / partnership economics from insurance-linked public cord blood access products (e.g., Public Bank Matching Protection Service launched in Taiwan with Taishin Life), with planned US and other-region rollouts supported by AI-driven matching.

prnewswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details6 tiers
1Cord blood banking plans (annual, 18-year prepaid, lifetime)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Published lifetime cord blood plan is $5,625 MSRP, advertised as 'less than $2 a day'; annual and 18-year prepaid plans also offered; 6 or 12 monthly payment plans available; $100 fee for overnight kit shipping; $200/year continuing storage after 18-year plan ends; free Sibling Donor Program for qualifying families.

stemcyte.com
2Public Bank Access (PBA) — $299 one-time add-on
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$299 one-time enrollment per child; covers the child only; includes up to $50,000 toward a matching donor unit from StemCyte's public bank, with global public bank search assistance. Available with any private banking plan.

stemcyte.com
3Public Bank Access+ (PBA+) — $699 one-time add-on
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$699 one-time enrollment; extends coverage to both parents — parents can access StemCyte's public bank inventory for cord blood transplant-eligible conditions even without their own banked cord blood. Available with any private banking plan.

stemcyte.com
4Newborn Genetic Analysis (NGA) — $399 one-time add-on
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$399 one-time Advanced Protection option with any cord blood banking plan; screens 258 genes / 200+ conditions using next-generation sequencing on the cord blood already collected at birth; results delivered to physician within 2–3 weeks; CLIA-certified, CAP-accredited lab.

stemcyte.com
5MaxCell® premium cord blood processing add-on
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Premium processing method (plasma depletion, 100 mL vs. ~25 mL standard) offered as an upgrade on storage plans; final pricing depends on the plan selected.

stemcyte.com
6Cord blood + cord tissue bundle
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Cord blood and cord tissue banking sold as a bundle with seasonal promotions such as $50–$100 off (e.g., Father's Day through June 30); lifetime storage option available.

stemcyte.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 5 records shown
1StemCyte Biologics
Description

Clinical development arm of StemCyte, Inc., advancing cord blood-derived cell therapies including REGENECYTE® and StemCyte-sponsored clinical trials in Long COVID, ischemic stroke, and cerebral palsy.

stemcyte.com
+4 more records
Core offering1 text field

StemCyte operates one of the only dual private and public cord blood banks in the U.S., selling family-directed cord blood and cord tissue banking plans directly to expectant parents, layered with Advanced Protection add-ons (MaxCell® premium processing, Newborn Genetic Analysis, Public Bank Access, HLA typing, LifeSaver Guarantee). Through its StemCyte Biologics division it develops REGENECYTE® — an FDA-licensed (US License 2280) allogeneic HPC, Cord Blood therapy — and supplies cord-derived cellular materials (cord blood, MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions, biotech developers, and clinical-trial sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85% fatigue resolution in REGENECYTE® Phase IIa Long COVID trial vs. 20% in placebo group (p < 0.01)
+4 more records
Product overview1 text field

StemCyte, Inc. operates a two-arm platform-plus-modules architecture: a Cord Blood Banking consumer service (both private family banking and public registry donation) supported by add-on modules such as Cord Tissue Banking, MaxCell® premium processing, HLA Typing, Newborn Genetic Analysis (NGA), Public Bank Access / Public Bank Access+, and the LifeSaver Guarantee; and a separate StemCyte Biologics division built around the FDA-licensed core therapy REGENECYTE® (HPC, Cord Blood, US License 2280), with its clinical pipeline (Long COVID, Acute Ischemic Stroke, Cerebral Palsy, and the IMPAACT P1107 HIV cure collaboration), an Expanded Access Program for Long COVID, and a B2B Cellular Materials catalog supplying fresh/frozen cord blood, cord tissue, MSCs, CD34+ HSPCs, and MSC exosomes to research and clinical-trial sponsors. The two arms share StemCyte's FACT- and AABB-accredited public cord blood bank and FDA-registered cGMP facility in Baldwin Park, California, and are coordinated through AI-driven donor matching and an FDA-licensed manufacturing/release-testing platform.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Taishin Life
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-05
Description

StemCyte International launched its Public Bank Matching Protection Service in Taiwan in partnership with Taishin Life, connecting insurance coverage to public cord blood resources and REGENECYTE® therapy. The collaboration is supported by StemCyte's AI-driven matching and manufacturing advancements and is described as the first insurance-linked public cord blood access product in Taiwan, with plans for further partnerships in the U.S. and other regions.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

City of Hope is one of the academic institutions listed by StemCyte Biologics as a customer / supporter that purchases cord-derived cellular materials for research and translational programs. Dr. Christine L. (Hematologist, City of Hope) provides a customer testimonial endorsing StemCyte. StemCyte's Chief Medical Officer Joseph Rosenthal, MD is also a Professor Emeritus at City of Hope.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials (cord blood, cord tissue, MSCs, CD34+ HSPCs, exosomes) for research and IND-enabling programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials for pediatric research and translational programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials for academic and translational research.

6IMPAACT Network (P1107 trial)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

StemCyte contributes cord blood units (including the CCR5Δ32/Δ32 homozygous unit) to the IMPAACT P1107 observational trial (NCT02140944) toward an HIV cure. The collaboration contributed to the 'New York Patient' case — the first possible HIV cure in a woman — published in Cell in 2023.

stemcyte.com
Strategic tierMinorTypeOthers
Description

NervGen Pharma is named in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key company developing emerging regenerative therapies and devices for SCI. The article references partnerships aimed at advancing regenerative treatments for spinal cord injury.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Named in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key organization developing regenerative treatments and devices for SCI.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Named in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key organization in SCI clinical research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1China Cord Blood Corporation
TypeRegional player
Description

China Cord Blood Corporation operates the largest cord blood banking network in China, a comparable private/public cord blood banking business model to StemCyte but focused exclusively on the Greater China market.

TypeEmerging player
Description

Mesoblast is a clinical-stage cell therapy company developing allogeneic MSC-based therapies (remestemcel-L, rexlemestrocel-L) for inflammatory and degenerative diseases, directly overlapping with StemCyte Biologics' cord-tissue MSC and regenerative-medicine pipeline.

TypeDirect peer
Description

Americord is one of the five major U.S. private cord blood banks named in StemCyte's competitive comparison, offering cord blood, cord tissue, and placental tissue banking plans to U.S. expectant parents.

TypeBroad incumbent
Description

Lonza is a global CDMO leader in cell and gene therapy manufacturing, including cGMP cord blood-derived and allogeneic cell therapy production; comparable to StemCyte's cGMP manufacturing platform from a buyer/competitor perspective in the Biologics B2B supply chain.

TypeEmerging player
Description

Celularity develops placenta-derived cellular therapies including allogeneic NK and MSC candidates, overlapping with StemCyte Biologics' REGENECYTE® and MSC exosome programs in regenerative medicine and cell therapy indications.

TypeBroad incumbent
Description

Hemacord was the first FDA-licensed HPC, Cord Blood product (2011) and is a direct regulatory peer to StemCyte's REGENECYTE® in the FDA-licensed allogeneic cord blood therapy category; provides a competitive benchmark for market access and pricing.

TypeDirect peer
Description

Cryo-Cell is one of StemCyte's two named FACT-accredited private U.S. cord blood bank peers, offering private and public cord blood banking plans, menstrual stem cell banking, and is a similarly long-tenured (founded 1989) U.S. competitor with comparable product structure.

TypeDirect peer
Description

CBR is the largest U.S. private cord blood bank and one of the five major competitors StemCyte benchmarks against; it offers comparable private banking plans and is a direct substitute at the point of sale to expectant parents.

TypeDirect peer
Description

NYBC operates one of the largest public cord blood banks in the U.S. and is a direct competitor to StemCyte's public bank; supplies donor units to NMDP-network transplant centers in overlapping therapeutic indications.

TypeDirect peer
Description

ViaCord is a long-established U.S. private cord blood bank, owned by Revvity (formerly PerkinElmer), and one of the five major U.S. private banks named in StemCyte's head-to-head comparison; competes directly on price, processing technology, and HLA-typing services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StemCyte

Cord Blood Banking Servicesstemcyte.com

StemCyte is a privately held U.S. cord blood bank and regenerative therapeutics company founded in 1997, operating private and public cord blood banking alongside FDA-licensed REGENECYTE® cell therapy, serving expectant parents, academic researchers, and clinical trial sponsors across 40 countries.

What StemCyte does

StemCyte, Inc. is a privately held U.S. cord blood banking and regenerative therapeutics company founded in 1997 and headquartered in Baldwin Park, California. The company operates a dual private-and-public cord blood bank under a single cGMP, FDA-licensed (US License 2280), FACT- and AABB-accredited platform. Its consumer-facing banking service offers annual, 18-year prepaid, and lifetime cord blood and cord tissue storage plans sold direct-to-consumer to U.S. expectant parents through a five-language website and an inside-sales call center, with add-on modules including MaxCell® premium processing, Newborn Genetic Analysis (a 258-gene NGS panel), Public Bank Access tiers, HLA typing, and a bundled LifeSaver Guarantee. Published lifetime MSRP is $5,625, positioned as the lowest among the five major U.S. private cord blood banks.

StemCyte generates revenue through a mix of one-time private-banking enrollment fees, recurring storage annuities, transaction-fee add-ons, B2B sales of cord-derived cellular materials (cord blood, Wharton's Jelly MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions and biotech developers, and long-tail licensing/royalty upside from REGENECYTE® (HPC, Cord Blood), an FDA-licensed allogeneic hematopoietic progenitor cell therapy with RMAT designation for Long COVID. The Biologics division is supported by a sponsored clinical pipeline across Long COVID, acute ischemic stroke, cerebral palsy, and a collaborative IMPAACT P1107 HIV cure study, plus an FDA-cleared Expanded Access Program for Long COVID.

Since 1997, StemCyte has delivered more than 2,300 cord blood units to over 325 transplant centers in 40 countries. Its customer base spans U.S. consumers (long-tail, one-decision-per-birth), B2B research buyers at institutions such as City of Hope, USC, CHLA, and UCLA, clinical trial sponsors, and — as of November 2025 — insurance-linked distribution partners beginning with Taishin Life in Taiwan. The company is privately held, with Diamond Biofund having invested US$6.35 million as part of a broader capital raise exceeding US$25 million announced in November 2023, alongside plans for a Taiwan Innovation Board listing.

StemCyte firmographics

Firmographics
Name
StemCyte
Legal name
StemCyte, Inc.
Website
https://stemcyte.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
StemCyte is a privately held U.S. cord blood bank and regenerative therapeutics company founded in 1997, operating private and public cord blood banking alongside FDA-licensed REGENECYTE® cell therapy, serving expectant parents, academic researchers, and clinical trial sponsors across 40 countries.
Ownership category
akta.pro rank

StemCyte industry classification

Industry
Product category
Cord Blood Banking Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Cord blood banking
  • Cellular therapy products
  • Stem cell therapeutics
  • Biological materials supply
  • Regenerative medicine research

Where StemCyte is headquartered

Location

Headquarters

HQ city
Baldwin Park
HQ country
United States
HQ region
North America

Offices3 records

Markets served

StemCyte business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Private cord blood banking plans: One-time enrollment revenue for cord blood and cord tissue storage plans (annual, 18-year prepaid, and lifetime options), plus optional split-pay over 6 or 12 months. The published lifetime cord blood plan is $5,625 MSRP — positioned as the lowest among the five major US private banks. Stored inventory scales with the number of enrolled families and forms a recurring annual storage annuity.
  2. Advanced Protection add-ons: One-time transaction-fee add-ons layered onto any private banking plan: MaxCell® premium processing, Newborn Genetic Analysis ($399), Public Bank Access ($299, covers the child) and Public Bank Access+ ($699, extends to parents). Each represents an incremental transaction with no recurring obligation.
  3. LifeSaver Guarantee and warranty economics: LifeSaver Guarantee is bundled free with every plan but creates contingent liability and a potential $50,000 payout obligation plus replacement unit from the public bank in the rare event of engraftment failure — a financial-services-style risk pool that is part of the value proposition and pricing logic.
  4. Biologics — cellular materials and research supply: B2B revenue from selling cord-derived cellular materials (whole cord blood units, cord tissue/Wharton's Jelly, MSCs, CD34+ HSPCs ≥90% purity, MSC exosomes, a cord blood cellular therapy product) as research-use and co-development starting materials to academic institutions, biotech developers, and clinical-trial sponsors. Includes custom specifications and pooled-donor formats on request.
  5. Clinical development and licensing (REGENECYTE®): Long-term value capture from REGENECYTE®, an FDA-licensed allogeneic HPC, Cord Blood therapy with RMAT designation for Long COVID, an FDA-cleared Expanded Access Program (2026), and three sponsored clinical trials (Long COVID Phase IIa, acute ischemic stroke Phase II, cerebral palsy Phase II). Includes data licensing, partnership, and future commercialization revenue tied to the cell therapy pipeline.
  6. Professional services — HLA typing and post-sale add-ons: One-time services such as HLA typing on privately banked units (so the unit's profile can be searched against registries if a family member needs treatment), Newborn Genetic Analysis reporting, and post-18-year continuing storage at $200/year or prepaid lifetime lock-in.
  7. Insurance-linked distribution partnerships: Revenue share / partnership economics from insurance-linked public cord blood access products (e.g., Public Bank Matching Protection Service launched in Taiwan with Taishin Life), with planned US and other-region rollouts supported by AI-driven matching.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCord blood banking plans (annual, 18-year prepaid, lifetime)
One time/ perpetual licensePay-as-you-goPublic Bank Access (PBA) — $299 one-time add-on
One time/ perpetual licensePay-as-you-goPublic Bank Access+ (PBA+) — $699 one-time add-on
One time/ perpetual licensePay-as-you-goNewborn Genetic Analysis (NGA) — $399 one-time add-on
One time/ perpetual licensePay-as-you-goMaxCell® premium cord blood processing add-on
SubscriptionPay-as-you-goCord blood + cord tissue bundle

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

StemCyte product offering

Product offering

Core offering

StemCyte operates one of the only dual private and public cord blood banks in the U.S., selling family-directed cord blood and cord tissue banking plans directly to expectant parents, layered with Advanced Protection add-ons (MaxCell® premium processing, Newborn Genetic Analysis, Public Bank Access, HLA typing, LifeSaver Guarantee). Through its StemCyte Biologics division it develops REGENECYTE® — an FDA-licensed (US License 2280) allogeneic HPC, Cord Blood therapy — and supplies cord-derived cellular materials (cord blood, MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions, biotech developers, and clinical-trial sponsors.

Product overview

StemCyte, Inc. operates a two-arm platform-plus-modules architecture: a Cord Blood Banking consumer service (both private family banking and public registry donation) supported by add-on modules such as Cord Tissue Banking, MaxCell® premium processing, HLA Typing, Newborn Genetic Analysis (NGA), Public Bank Access / Public Bank Access+, and the LifeSaver Guarantee; and a separate StemCyte Biologics division built around the FDA-licensed core therapy REGENECYTE® (HPC, Cord Blood, US License 2280), with its clinical pipeline (Long COVID, Acute Ischemic Stroke, Cerebral Palsy, and the IMPAACT P1107 HIV cure collaboration), an Expanded Access Program for Long COVID, and a B2B Cellular Materials catalog supplying fresh/frozen cord blood, cord tissue, MSCs, CD34+ HSPCs, and MSC exosomes to research and clinical-trial sponsors. The two arms share StemCyte's FACT- and AABB-accredited public cord blood bank and FDA-registered cGMP facility in Baldwin Park, California, and are coordinated through AI-driven donor matching and an FDA-licensed manufacturing/release-testing platform.

Differentiator

Problem solved

Functional benefit

Brands

  • StemCyte Biologics: Clinical development arm of StemCyte, Inc., advancing cord blood-derived cell therapies including REGENECYTE® and StemCyte-sponsored clinical trials in Long COVID, ischemic stroke, and cerebral palsy.
  • REGENECYTE®
  • MaxCell®
  • Public Bank Access (PBA)
  • LifeSaver Guarantee

Quantifiable outcome

  • 85% fatigue resolution in REGENECYTE® Phase IIa Long COVID trial vs. 20% in placebo group (p < 0.01)
  • +4 more outcomes

Companies that use StemCyte

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

StemCyte technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

StemCyte partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

  • Taishin LifeflagshipChannel Partner/ Reseller/ Distributor · 5 November 2025StemCyte International launched its Public Bank Matching Protection Service in Taiwan in partnership with Taishin Life, connecting insurance coverage to public cord blood resources and REGENECYTE® therapy. The collaboration is supported by StemCyte's AI-driven matching and manufacturing advancements and is described as the first insurance-linked public cord blood access product in Taiwan, with plans for further partnerships in the U.S. and other regions.
  • City of HopecoreStrategic or Co-development PartnerCity of Hope is one of the academic institutions listed by StemCyte Biologics as a customer / supporter that purchases cord-derived cellular materials for research and translational programs. Dr. Christine L. (Hematologist, City of Hope) provides a customer testimonial endorsing StemCyte. StemCyte's Chief Medical Officer Joseph Rosenthal, MD is also a Professor Emeritus at City of Hope.
  • USC (University of Southern California)minorStrategic or Co-development PartnerListed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials (cord blood, cord tissue, MSCs, CD34+ HSPCs, exosomes) for research and IND-enabling programs.
  • CHLA (Children's Hospital Los Angeles)minorStrategic or Co-development PartnerListed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials for pediatric research and translational programs.
  • UCLAminorStrategic or Co-development PartnerListed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials for academic and translational research.
  • IMPAACT Network (P1107 trial)coreStrategic or Co-development PartnerStemCyte contributes cord blood units (including the CCR5Δ32/Δ32 homozygous unit) to the IMPAACT P1107 observational trial (NCT02140944) toward an HIV cure. The collaboration contributed to the 'New York Patient' case — the first possible HIV cure in a woman — published in Cell in 2023.
  • NervGen PharmaminorOthersNervGen Pharma is named in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key company developing emerging regenerative therapies and devices for SCI. The article references partnerships aimed at advancing regenerative treatments for spinal cord injury.
  • VA Office of Research and DevelopmentminorStrategic or Co-development PartnerNamed in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key organization developing regenerative treatments and devices for SCI.
  • Kessler Foundation / Kessler InstituteminorStrategic or Co-development PartnerNamed in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key organization in SCI clinical research.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

StemCyte competitors and assessment

Company assessment

Regional players

  • China Cord Blood Corporation: China Cord Blood Corporation operates the largest cord blood banking network in China, a comparable private/public cord blood banking business model to StemCyte but focused exclusively on the Greater China market.

Emerging players

  • Mesoblast Limited: Mesoblast is a clinical-stage cell therapy company developing allogeneic MSC-based therapies (remestemcel-L, rexlemestrocel-L) for inflammatory and degenerative diseases, directly overlapping with StemCyte Biologics' cord-tissue MSC and regenerative-medicine pipeline.
  • Celularity Inc. Celularity develops placenta-derived cellular therapies including allogeneic NK and MSC candidates, overlapping with StemCyte Biologics' REGENECYTE® and MSC exosome programs in regenerative medicine and cell therapy indications.

Direct peers

  • Americord Registry: Americord is one of the five major U.S. private cord blood banks named in StemCyte's competitive comparison, offering cord blood, cord tissue, and placental tissue banking plans to U.S. expectant parents.
  • Cryo-Cell International: Cryo-Cell is one of StemCyte's two named FACT-accredited private U.S. cord blood bank peers, offering private and public cord blood banking plans, menstrual stem cell banking, and is a similarly long-tenured (founded 1989) U.S. competitor with comparable product structure.
  • Cord Blood Registry (CBR) by Generate Life Sciences: CBR is the largest U.S. private cord blood bank and one of the five major competitors StemCyte benchmarks against; it offers comparable private banking plans and is a direct substitute at the point of sale to expectant parents.
  • New York Blood Center (National Cord Blood Program): NYBC operates one of the largest public cord blood banks in the U.S. and is a direct competitor to StemCyte's public bank; supplies donor units to NMDP-network transplant centers in overlapping therapeutic indications.
  • ViaCord (Revvity): ViaCord is a long-established U.S. private cord blood bank, owned by Revvity (formerly PerkinElmer), and one of the five major U.S. private banks named in StemCyte's head-to-head comparison; competes directly on price, processing technology, and HLA-typing services.

Broad incumbents

  • Lonza Cell & Gene Therapies: Lonza is a global CDMO leader in cell and gene therapy manufacturing, including cGMP cord blood-derived and allogeneic cell therapy production; comparable to StemCyte's cGMP manufacturing platform from a buyer/competitor perspective in the Biologics B2B supply chain.
  • Hemacord (New York Blood Center / FDA HPC, Cord Blood): Hemacord was the first FDA-licensed HPC, Cord Blood product (2011) and is a direct regulatory peer to StemCyte's REGENECYTE® in the FDA-licensed allogeneic cord blood therapy category; provides a competitive benchmark for market access and pricing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

StemCyte social profiles

Digital presence

StemCyte compliance and trust

Trust signal

Compliance9 records

StemCyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StemCyte leadership team

Management profile

Number of profiles

Profiles4 records

StemCyte subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

StemCyte funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StemCyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemCyte

What does StemCyte do?

StemCyte operates one of the only dual private and public cord blood banks in the U.S., selling family-directed cord blood and cord tissue banking plans directly to expectant parents, layered with Advanced Protection add-ons (MaxCell® premium processing, Newborn Genetic Analysis, Public Bank Access, HLA typing, LifeSaver Guarantee). Through its StemCyte Biologics division it develops REGENECYTE® — an FDA-licensed (US License 2280) allogeneic HPC, Cord Blood therapy — and supplies cord-derived cellular materials (cord blood, MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions, biotech developers, and clinical-trial sponsors.

Is StemCyte a public or private company?

StemCyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was StemCyte founded?

StemCyte was founded in 1997. It employs 101 to 250 people.

Where is StemCyte based?

StemCyte is headquartered in Baldwin Park, United States, in the North America region.

How does StemCyte make money?

Seven revenue lines are on record. Private cord blood banking plans are the primary driver. The others are advanced Protection add-ons, lifeSaver Guarantee and warranty economics, biologics — cellular materials and research supply, clinical development and licensing (REGENECYTE®), professional services — HLA typing and post-sale add-ons and insurance-linked distribution partnerships.

Who are StemCyte's main competitors?

China Cord Blood Corporation is listed as a regional player. Emerging players are Mesoblast Limited and Celularity Inc.. Direct peers are Americord Registry, Cryo-Cell International, Cord Blood Registry (CBR) by Generate Life Sciences, New York Blood Center (National Cord Blood Program) and ViaCord (Revvity). Broad incumbents are Lonza Cell & Gene Therapies and Hemacord (New York Blood Center / FDA HPC, Cord Blood).

Does StemCyte have an API?

No public API is recorded for StemCyte.

What industry is StemCyte in?

StemCyte's product category is Cord Blood Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StemcyteAbout StemCyte Biologics (TWSE 4178)StemCyte, founded in 1997, operates cord blood banking and regenerative cell therapy in the US and Taiwan, holding FACT and AABB accreditation and an FDA-licensed cGMP facility. In 2024, it received FDA biologics license approval for REGENECYTE and RMAT designation for Long COVID, and won Taiwan BIO Award for Innovation of the Year.openPR.comSpinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, KesslerDelveInsight released its 'Spinal Cord Injury Pipeline Insight, 2026' report covering 30+ therapies under development by 25+ companies, including updates on clinical trials for treatments such as NVG-291 (NervGen Pharma), OPC1 (Lineage Cell Therapeutics), and ExoPTEN (NurExone Biologic). Key recent developments include NurExone Biologic's completion of a preclinical study supporting its IND application in March 2025 and Lineage Cell Therapeutics' launch of the DOSED clinical study for its OPC1 therapy delivery system in February 2025. A pilot trial at the University of Pittsburgh in February 2025 demonstrated that Medtronic's spinal cord stimulation device improved walking distance by at least 20 meters in all three SMA patients tested.PR NewswireStemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVIDThe FDA has cleared StemCyte's Expanded Access program for RegeneCyte®, an FDA-licensed HPC cord blood therapy, enabling eligible Long COVID patients to access the treatment while pivotal clinical research continues. Phase IIa trial data showed 85% of treated patients experienced statistically significant resolution of chronic fatigue compared to 20% in the placebo group. The therapy holds Regenerative Medicine Advanced Therapy designation and is currently the only FDA-licensed cord blood product in U.S. clinical trials for Long COVID.PR NewswireStemCyte Launches First Insurance-Linked Public Cord Blood Access in Taiwan, Setting a New Standard in Cell Therapy ProtectionStemCyte International launched its Public Bank Matching Protection Service in Taiwan, connecting insurance coverage to public cord blood resources in collaboration with Taishin Life. The service features REGENECYTE®, an FDA-approved therapy for unrelated allogeneic transplantation, supporting the company's efforts to expand access to cell therapy. Plans are underway for further partnerships in the United States and other regions, supported by AI-driven matching and manufacturing advancements.PR NewswireStemCyte Renews Contract with the California State Umbilical Cord Blood Collection ProgramStemCyte renewed its partnership with the California State Umbilical Cord Blood Collection Program, with UC Davis Health. The enhanced contract includes additional funding to diversify the NMDP National Registry and plans for new collection sites in Palm Springs and Sacramento. StemCyte has supplied over 2,300 cord blood units for transplants since 2013.DiamondbiofundDiamond Biofund Leads StemCyte’s Capital Increase of over US$25M – Diamond BiofundDiamond Biofund announced a US$6.35 million investment in StemCyte, contributing to the latter's successful capital raise of over US$25 million. This funding supports StemCyte's global expansion of its novel allogeneic cell therapy and ongoing clinical trials for conditions such as post-COVID-19 syndrome and spinal cord injuries. StemCyte also plans to apply for listing on the Taiwan Innovation Board by the end of 2023.PR NewswireSpinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVieDelveInsight released a market report forecasting substantial growth in the spinal cord injury market through 2032, driven by improved diagnostics and emerging therapies. The analysis highlights key industry players including NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, and AbbVie who are developing novel treatments for the condition.PR NewswireThe first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients.StemCyte has officially begun recruiting patients for the world's first FDA-approved Phase IIa clinical trial using umbilical cord blood cells to treat Post-COVID syndrome, conducted in the United States. The trial also represents the first approved design for administering multiple doses of cord blood cell therapy and targets chronic fatigue associated with Post-COVID symptoms. An estimated 60 million people worldwide—approximately 10% of those infected since 2019—develop persistent Post-COVID symptoms for which no effective treatment currently exists.PR NewswireStemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell TherapyStemCyte, a Southern California cord blood regenerative therapeutics company, has received FDA approval to proceed with a Phase II clinical trial for Post-COVID Syndrome (Long COVID) using umbilical cord blood stem cell therapy. The trial targets PCS, a condition affecting an estimated 7.7 to 23 million people in the United States and 51% of COVID-19 patients in Asia, characterized by persistent symptoms such as breathlessness, fatigue, brain fog, and anxiety that can last years. The company aims to leverage umbilical cord blood's anti-inflammatory and tissue repair properties to achieve long-term systemic efficacy, addressing a condition for which current treatments only temporarily ameliorate specific symptoms.PR NewswireStemCyte, a leading regenerative cell therapy company, has submitted its application for a biologics license (BLA) for its allogeneic umbilical cord hematopoietic progenitor cell product "HPC-Cord BloStemCyte submitted its Biologics License Application (BLA) for the "HPC-Cord Blood" product to the FDA on January 7th, 2022, and was notified on March 8th, 2022 that the submission was accepted for quality review. The product is an umbilical cord blood hematopoietic stem cell intended for unrelated donor hematopoietic progenitor cell transplantation procedures, and StemCyte anticipates receiving licensure in 2023. The company has provided over 2,200 cord blood units for transplantation in the past 20 years and is recognized by approximately 350 transplant centers worldwide.